| Shannon, Chris; Merovci, Aurora; Xiong, Juan et al. (2018) Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance. Diabetes 67:2507-2517 |
| DeFronzo, Ralph A (2017) Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 19:1353-1362 |
| Abdul-Ghani, Muhammad; DeFronzo, Ralph A; Del Prato, Stefano et al. (2017) Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 40:813-820 |
| Abdul-Ghani, Muhammad; DeFronzo, Ralph A (2017) Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. Diabetes Care 40:1121-1127 |
| Merovci, Aurora; Abdul-Ghani, Muhammad; Mari, Andrea et al. (2016) Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males. J Clin Endocrinol Metab 101:1249-56 |
| DeFronzo, Ralph A (2016) The EMPA-REG study: What has it told us? A diabetologist's perspective. J Diabetes Complications 30:1-2 |
| Daniele, Giuseppe; Xiong, Juan; Solis-Herrera, Carolina et al. (2016) Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care 39:2036-2041 |
| Abdul-Ghani, Muhammad; Del Prato, Stefano; Chilton, Robert et al. (2016) SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care 39:717-25 |
| DeFronzo, Ralph A; Ferrannini, Ele; Groop, Leif et al. (2015) Type 2 diabetes mellitus. Nat Rev Dis Primers 1:15019 |
| Abdul-Ghani, Muhammad A; Norton, Luke; DeFronzo, Ralph A (2015) Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol 309:F889-900 |
Showing the most recent 10 out of 40 publications
